ArticleLife (Basel, Switzerland)2026
Interleukin-6 in Daily Use in the Intensive Care Unit: Does It Change the Patients' Outcome and Antimicrobial Prescription? An Explorative Study.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-6 (IL-6) rises rapidly during systemic inflammation and is used in some ICUs as a daily infection marker. Whether routine IL-6 monitoring affects patient outcomes or antimicrobial use, compared with standard biomarkers CRP/PCT, remains unclear.
methodsThis retrospective two-step study was conducted at a tertiary interdisciplinary ICU in Wiesbaden, Germany. Step 1 (pilot cohort) compared two 2-month periods with routine IL-6 versus CRP/PCT testing to identify differences and generate assumptions. Step 2 (extended cohort) compared two consecutive 12-month periods before and after discontinuation of IL-6 testing. After matching for disease severity and specialty, endpoints included ICU length of stay, ventilation hours, mortality, and antimicrobial use measured as defined daily doses (DDD), and recommended daily doses (RDD) per 100 patient-days.
resultsResults: In the pilot cohort (n = 221), there were no significant differences between the IL-6 and CRP/PCT groups in terms of anti-infective therapy or ventilation hours. In the extended cohort (n = 5146), case-matched analyses showed no significant group differences in ICU length of stay, ventilation hours, or mortality between groups. Antimicrobial consumption was higher when IL-6 was used: DDD (16.8% increase, rate ratio RR = 1.17, 95% CI (1.14, 1.19),
conclusionsIn this exploratory study, routine IL-6 testing was not associated with improved outcomes but might be linked to increased antimicrobial consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.